These inhibitors include, among others, SNX-5422 for chronic lymphocytic leukemia (combined with ibrutinib, phase 1) and AT13387 for EGFR-mutant lung cancer (combined with erlotinib hydrochloride, phase 1–2). This evidence concerns the gene EGFR and B-cell chronic lymphocytic leukemia.